Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2

Jaishri O. Blakeley, D. Gareth Evans, John Adler, Derald Brackmann, Ruihong Chen, Rosalie E. Ferner, C. Oliver Hanemann, Gordon Harris, Susan M. Huson, Abraham Jacob, Michel Kalamarides, Matthias A. Karajannis, Bruce R. Korf, Victor Felix Mautner, Andrea I. Mcclatchey, Harry Miao, Scott R. Plotkin, William Slattery, Anat O. Stemmer-Rachamimov, D. Bradley Welling & 4 others Patrick Y. Wen, Brigitte Widemann, Kim Hunter-Schaedle, Marco Giovannini

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Neurofibromatosis type 2 (NF2) is a tumor suppressor syndrome characterized by bilateral vestibular schwannomas (VS) which often result in deafness despite aggressive management. Meningiomas, ependymomas, and other cranial nerve and peripheral schwannomas are also commonly found in NF2 and collectively lead to major neurologic morbidity and mortality. Traditionally, the overall survival rate in patients with NF2 is estimated to be 38% at 20 years from diagnosis. Hence, there is a desperate need for new, effective therapies. Recent progress in understanding the molecular basis of NF2 related tumors has aided in the identification of potential therapeutic targets and emerging clinical therapies. In June 2010, representatives of the international NF2 research and clinical community convened under the leadership of Drs. D. Gareth Evans (University of Manchester) and Marco Giovannini (House Research Institute) to review the state of NF2 treatment and clinical trials. This manuscript summarizes the expert opinions about current treatments for NF2 associated tumors and recommendations for advancing therapies emerging from that meeting. The development of effective therapies for NF2 associated tumors has the potential for significant clinical advancement not only for patients with NF2 but for thousands of neuro-oncology patients afflicted with these tumors.

Original languageEnglish (US)
Pages (from-to)24-41
Number of pages18
JournalAmerican Journal of Medical Genetics, Part A
Volume158 A
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

Fingerprint

Neurofibromatosis 2
Consensus
Clinical Trials
Therapeutics
Neoplasms
Ependymoma
Acoustic Neuroma
Cranial Nerves
Neurilemmoma
Expert Testimony
Meningioma
Deafness
Nervous System
Survival Rate
Morbidity

Keywords

  • Ependymoma
  • Meningioma
  • Molecular therapy
  • Neurofibromatosis type 2
  • Radiotherapy
  • Schwannoma
  • Surgery
  • Vestibular schwannoma

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. / Blakeley, Jaishri O.; Evans, D. Gareth; Adler, John; Brackmann, Derald; Chen, Ruihong; Ferner, Rosalie E.; Hanemann, C. Oliver; Harris, Gordon; Huson, Susan M.; Jacob, Abraham; Kalamarides, Michel; Karajannis, Matthias A.; Korf, Bruce R.; Mautner, Victor Felix; Mcclatchey, Andrea I.; Miao, Harry; Plotkin, Scott R.; Slattery, William; Stemmer-Rachamimov, Anat O.; Welling, D. Bradley; Wen, Patrick Y.; Widemann, Brigitte; Hunter-Schaedle, Kim; Giovannini, Marco.

In: American Journal of Medical Genetics, Part A, Vol. 158 A, No. 1, 01.2012, p. 24-41.

Research output: Contribution to journalArticle

Blakeley, JO, Evans, DG, Adler, J, Brackmann, D, Chen, R, Ferner, RE, Hanemann, CO, Harris, G, Huson, SM, Jacob, A, Kalamarides, M, Karajannis, MA, Korf, BR, Mautner, VF, Mcclatchey, AI, Miao, H, Plotkin, SR, Slattery, W, Stemmer-Rachamimov, AO, Welling, DB, Wen, PY, Widemann, B, Hunter-Schaedle, K & Giovannini, M 2012, 'Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2', American Journal of Medical Genetics, Part A, vol. 158 A, no. 1, pp. 24-41. https://doi.org/10.1002/ajmg.a.34359
Blakeley, Jaishri O. ; Evans, D. Gareth ; Adler, John ; Brackmann, Derald ; Chen, Ruihong ; Ferner, Rosalie E. ; Hanemann, C. Oliver ; Harris, Gordon ; Huson, Susan M. ; Jacob, Abraham ; Kalamarides, Michel ; Karajannis, Matthias A. ; Korf, Bruce R. ; Mautner, Victor Felix ; Mcclatchey, Andrea I. ; Miao, Harry ; Plotkin, Scott R. ; Slattery, William ; Stemmer-Rachamimov, Anat O. ; Welling, D. Bradley ; Wen, Patrick Y. ; Widemann, Brigitte ; Hunter-Schaedle, Kim ; Giovannini, Marco. / Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. In: American Journal of Medical Genetics, Part A. 2012 ; Vol. 158 A, No. 1. pp. 24-41.
@article{78ff352cb66c4986b1d89a0fcea9390a,
title = "Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2",
abstract = "Neurofibromatosis type 2 (NF2) is a tumor suppressor syndrome characterized by bilateral vestibular schwannomas (VS) which often result in deafness despite aggressive management. Meningiomas, ependymomas, and other cranial nerve and peripheral schwannomas are also commonly found in NF2 and collectively lead to major neurologic morbidity and mortality. Traditionally, the overall survival rate in patients with NF2 is estimated to be 38{\%} at 20 years from diagnosis. Hence, there is a desperate need for new, effective therapies. Recent progress in understanding the molecular basis of NF2 related tumors has aided in the identification of potential therapeutic targets and emerging clinical therapies. In June 2010, representatives of the international NF2 research and clinical community convened under the leadership of Drs. D. Gareth Evans (University of Manchester) and Marco Giovannini (House Research Institute) to review the state of NF2 treatment and clinical trials. This manuscript summarizes the expert opinions about current treatments for NF2 associated tumors and recommendations for advancing therapies emerging from that meeting. The development of effective therapies for NF2 associated tumors has the potential for significant clinical advancement not only for patients with NF2 but for thousands of neuro-oncology patients afflicted with these tumors.",
keywords = "Ependymoma, Meningioma, Molecular therapy, Neurofibromatosis type 2, Radiotherapy, Schwannoma, Surgery, Vestibular schwannoma",
author = "Blakeley, {Jaishri O.} and Evans, {D. Gareth} and John Adler and Derald Brackmann and Ruihong Chen and Ferner, {Rosalie E.} and Hanemann, {C. Oliver} and Gordon Harris and Huson, {Susan M.} and Abraham Jacob and Michel Kalamarides and Karajannis, {Matthias A.} and Korf, {Bruce R.} and Mautner, {Victor Felix} and Mcclatchey, {Andrea I.} and Harry Miao and Plotkin, {Scott R.} and William Slattery and Stemmer-Rachamimov, {Anat O.} and Welling, {D. Bradley} and Wen, {Patrick Y.} and Brigitte Widemann and Kim Hunter-Schaedle and Marco Giovannini",
year = "2012",
month = "1",
doi = "10.1002/ajmg.a.34359",
language = "English (US)",
volume = "158 A",
pages = "24--41",
journal = "American Journal of Medical Genetics, Part A",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2

AU - Blakeley, Jaishri O.

AU - Evans, D. Gareth

AU - Adler, John

AU - Brackmann, Derald

AU - Chen, Ruihong

AU - Ferner, Rosalie E.

AU - Hanemann, C. Oliver

AU - Harris, Gordon

AU - Huson, Susan M.

AU - Jacob, Abraham

AU - Kalamarides, Michel

AU - Karajannis, Matthias A.

AU - Korf, Bruce R.

AU - Mautner, Victor Felix

AU - Mcclatchey, Andrea I.

AU - Miao, Harry

AU - Plotkin, Scott R.

AU - Slattery, William

AU - Stemmer-Rachamimov, Anat O.

AU - Welling, D. Bradley

AU - Wen, Patrick Y.

AU - Widemann, Brigitte

AU - Hunter-Schaedle, Kim

AU - Giovannini, Marco

PY - 2012/1

Y1 - 2012/1

N2 - Neurofibromatosis type 2 (NF2) is a tumor suppressor syndrome characterized by bilateral vestibular schwannomas (VS) which often result in deafness despite aggressive management. Meningiomas, ependymomas, and other cranial nerve and peripheral schwannomas are also commonly found in NF2 and collectively lead to major neurologic morbidity and mortality. Traditionally, the overall survival rate in patients with NF2 is estimated to be 38% at 20 years from diagnosis. Hence, there is a desperate need for new, effective therapies. Recent progress in understanding the molecular basis of NF2 related tumors has aided in the identification of potential therapeutic targets and emerging clinical therapies. In June 2010, representatives of the international NF2 research and clinical community convened under the leadership of Drs. D. Gareth Evans (University of Manchester) and Marco Giovannini (House Research Institute) to review the state of NF2 treatment and clinical trials. This manuscript summarizes the expert opinions about current treatments for NF2 associated tumors and recommendations for advancing therapies emerging from that meeting. The development of effective therapies for NF2 associated tumors has the potential for significant clinical advancement not only for patients with NF2 but for thousands of neuro-oncology patients afflicted with these tumors.

AB - Neurofibromatosis type 2 (NF2) is a tumor suppressor syndrome characterized by bilateral vestibular schwannomas (VS) which often result in deafness despite aggressive management. Meningiomas, ependymomas, and other cranial nerve and peripheral schwannomas are also commonly found in NF2 and collectively lead to major neurologic morbidity and mortality. Traditionally, the overall survival rate in patients with NF2 is estimated to be 38% at 20 years from diagnosis. Hence, there is a desperate need for new, effective therapies. Recent progress in understanding the molecular basis of NF2 related tumors has aided in the identification of potential therapeutic targets and emerging clinical therapies. In June 2010, representatives of the international NF2 research and clinical community convened under the leadership of Drs. D. Gareth Evans (University of Manchester) and Marco Giovannini (House Research Institute) to review the state of NF2 treatment and clinical trials. This manuscript summarizes the expert opinions about current treatments for NF2 associated tumors and recommendations for advancing therapies emerging from that meeting. The development of effective therapies for NF2 associated tumors has the potential for significant clinical advancement not only for patients with NF2 but for thousands of neuro-oncology patients afflicted with these tumors.

KW - Ependymoma

KW - Meningioma

KW - Molecular therapy

KW - Neurofibromatosis type 2

KW - Radiotherapy

KW - Schwannoma

KW - Surgery

KW - Vestibular schwannoma

UR - http://www.scopus.com/inward/record.url?scp=84355166399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84355166399&partnerID=8YFLogxK

U2 - 10.1002/ajmg.a.34359

DO - 10.1002/ajmg.a.34359

M3 - Article

VL - 158 A

SP - 24

EP - 41

JO - American Journal of Medical Genetics, Part A

JF - American Journal of Medical Genetics, Part A

SN - 1552-4825

IS - 1

ER -